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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
30.11.2020 Olfactory 
transmucosal 
SARS-CoV-2 
invasion as a 
port of 
central 
nervous 
system entry 
in individuals 
with COVID-
19 
Nature 
Neuroscience 
| Article 
• An autopsy study which 
suggests that SARS-CoV-2 
may enter the brain of 
people through the nose 
• May help explain some of 
the neurological symptoms 
observed in COVID-19 
patients and may inform 
diagnosis and measures to 
prevent infection 
Viral 
entry, 
nervous 
system 
26.11.2020 Thoracic 
imaging tests 
for the 
diagnosis of 
COVID-19 
Cochrane | 
Diagnostic 
Systematic 
Review 
• First update of this ‘living 
systematic review’ – shows 
change in accuracy from 
initial review to this update 
(more and higher quality 
studies). This update 
focuses on people 
suspected of having 
COVID-19 and excludes 
studies with only confirmed 
COVID-19 participants 
• Findings indicate that chest 
CT is sensitive and 
moderately specific for the 
diagnosis of COVID-19 in 
CT, 
diagnosis 
suspected patients 
suggesting that CT could 
play a limited role in 
differentiating SARS-CoV-2 
infection from other causes 
of respiratory illness  
• Because of limited data, 
accuracy estimates of chest 
X-ray and ultrasound of the 
lungs for the diagnosis of 
suspected COVID-19 cases 
should be carefully 
interpreted 
• Includes recommendations 
for future diagnostic 
accuracy studies 
24.11.2020 Association 
between 
ABO and Rh 
blood groups 
and SARS-
CoV-2 
infection or 
severe 
COVID-19 
illness 
Annals of 
Internal 
Medicine | 
Original 
Research  
• To determine whether ABO 
and Rh blood groups are 
associated with risk for 
SARS-CoV-2 infection and 
severe COVID-19 
• Population-based cohort 
study of 225, 556 
persons  in Ontario, Canada 
• The O and Rh- blood 
groups may be associated 
with a slightly lower risk for 
SARS-CoV-2 infection and 
severe COVID-19 illness 
Blood 
group, 
infection, 
severe 
COVID-
19 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
27.11.2020 SARS-CoV-2 
setting-
specific 
transmission 
rates: a 
systematic 
review and 
meta-analysis 
ICL | Report 
38 
• Understanding the 
drivers of SARS-CoV-
2 transmission is 
crucial for disease 
control policies but 
evidence of 
transmission rates in 
different settings 
remains limited 
• A systematic review to 
estimate the 
secondary attack rate 
(SAR) and observed 
reproduction number 
(Robs) in different 
settings and to explore 
differences by age, 
symptom status, 
Transmission, 
setting-
specific 
duration of exposure 
and household size 
• Households showed 
the highest 
transmission rates with 
pooled SAR and Robs 
estates of 21.1% (95% 
CI: 17.4-24.8%) and 
0.96 (95%CI: 0.67-
1.32), respectively 
• Household SAR 
estimates were 
significantly higher 
where duration of 
household exposure 
exceeded 5 days 
compared with 
exposure of 5 days or 
less 
• Attack rates were 
higher with prolonged 
close contacts (e.g. 
social events with 
family and friends) 
compared with casual 
contact, such as with 
strangers 
• Estimates of SAR for 
asymptomatic index 
cases were approx. 
two thirds of those for 
symptomatic index 
• Moderate evidence for 
less transmission both 
from and to individuals 
under 20 years of age 
in household context, 
but less evidence 
when examining all 
settings 
• Limited data to explore 
transmission patterns 
in workplaces, schools 
and care-homes 
25.11.2020 Children’s role 
in the COVID-
19 pandemic: 
a systematic 
review of 
susceptibility, 
severity, and 
transmissibility 
ICL | Report 
37 
• Systematic review of 
early studies 
synthesising evidence 
on the susceptibility of 
children to SARS-CoV-
2 infection, the severity 
and clinical outcomes 
in children with SARS-
CoV-2 infection, and 
the transmissibility of 
children, 
susceptibility, 
severity, 
transmission 
SARS-CoV-2 by 
children 
• A final 29 studies were 
considered for meta-
analysis that included 
information of 
symptoms and/or 
severity. No studies 
were identified that 
were designed to 
assess transmissibility 
in children 
• Children’s 
susceptibility to 
infection and onward 
transmissibility relative 
to adults is still unclear 
and varied widely 
between studies 
• It is evidence that most 
children experience 
clinically mild disease 
or main 
asymptomatically 
infected 
• More comprehensive 
contract-tracing 
studies combined with 
serosurveys are 
needed to quantify 
children’s 
transmissibility relative 
to adults 
Therapeutics 
Publication 
date 
Title/URL Journal/Articl
e type 
Summary             Keywords 
24.11.2020 A cluster-
randomised 
trial of 
hydroxychloroq
uine for 
prevention of 
Covid-19 
NEJM | 
Article 
• Hydroxychloroqui
ne has been 
proposed as a 
postexposure 
therapy to 
prevent Covid-19, 
but definitive 
evidence is 
lacking 
• Open-label, 
cluster-
randomised trial 
involving 2314 
healthy 
Hydroxychloroquin
e, prevention 
asymptomatic 
contacts of 672 
patients with 
PCR-confirmed 
Covid-19 in Spain  
• Postexposure 
therapy in 
hydroxychloroqui
ne did not prevent 
SARS-CoV-2 
infection or 
symptomatic 
Covid-19 in 
healthy persons 
exposed to a 
PCR-positive 
index case 
24.11.2020 A randomized 
trial of 
convalescent 
plasma in 
COVID-19 
severe 
pneumonia 
NEJM | 
Article 
• Randomised, 
placebo-
controlled trial of 
convalescent 
plasma for severe 
COVID-19 
• Primary outcome 
was patient’s’ 
clinical status 30 
days after the 
intervention 
(n=228 CP, 
n=105 placebo) 
• No significant 
differences 
observed in 
clinical status or 
overall mortality 
in patients treated 
with convalescent 
plasma compared 
with those who 
received placebo  
• Use of 
convalescent 
plasma as a 
standard of care 
should be re-
evaluated 
Convalescent 
plasma, severe 
COVID-19 
21.11.2020 Prevention of 
severe COVID-
19 in the elderly 
by early high-
titer plasma 
medRxiv | 
pre-print 
(non-peer 
reviewed) 
• Early evidence 
suggests 
convalescent 
plasma in 
hospitalised 
patients may be 
unsuccessful in 
preventing 
 Convalescent 
plasma, mild 
COVID-19 
progression of 
COVID-19  
• Randomised, 
double-blind, 
placebo-
controlled trial of 
convalescent 
plasma with high 
IgG titers against 
SARS-CoV-2 in 
160 elderly 
subjects in 
Argentina within 
72 hours of mild 
COVID-19 
symptoms  
• Early 
administration of 
high-titer 
convalescent 
plasma reduced 
mild COVID-19 
progression  
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
   
• No new articles found this 
week 
 
   
• Refer to Comments, 
Editorials, Opinions, Blogs, 
News Section below for 
press releases on vaccine 
candidates 
 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
2020 COVID-
19: 
Violence 
risk and 
income 
loss 
among 
ADD 
International | 
Report 
• This report presents findings 
from telephone interviews with 
87 members from Disabled 
People’s Organisation (DPO) 
partners and 10 DPO/Self-Help 
Group (SHG) leaders from 
organisations with 1,998 
members in 10 districts across 
7 provinces of Cambodia to 
Persons 
with 
disabilities, 
Cambodia 
persons 
with 
disabilities 
ask about the impact of the 
COVID-19 pandemic on 
persons with disabilities 
• Three patterns emerge: (1) 
there is a pattern of 
compounding vulnerability to 
violence; (2) a pattern of 
significant livelihood loss that 
is felt differently by disability 
type and gender; and (3) a link 
between livelihood loss and 
pronounced increase in 
economic and psychological 
violence against women and 
girls with disabilities 
 Leadership and governance 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
24.11.2020 WICID 
framework 
version 1.0: 
criteria and 
considerations 
to guide 
evidence-
informed 
decision-making 
on non-
pharmacological 
interventions 
targeting 
COVID-19  
BMJ Global 
Health | 
Original 
Research  
• Decision-makers need 
to balance numerous 
and often conflicting 
factors when making 
ad hoc decisions on 
public health matters 
and health policy with 
insufficient 
consideration of 
relevant factors 
reducing acceptance, 
limiting effectiveness 
• Here authors develop 
a decision-making 
“WICID” framework 
that provides 11+1 
criteria informed by 47 
aspects, intended to 
support decision-
making on non-
pharmacological 
interventions to 
contain the global 
SARS-CoV-2 
pandemic 
• Usage of the 
framework aims to 
support balanced 
decision-making, even 
if not all voices of 
EIDM, 
framework 
relevant stakeholders 
could be included in 
the process due to 
time constraints 
imposed by the rapid 
progress of the 
pandemic 
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
30.11.2020 Covid vaccine: Moderna seeks approval in US 
and Europe 
BBC | News 
30.11.2020 ‘Absolutely remarkable’: No one who got 
Moderna’s vaccine in trial developed severe 
COVID-19 
Science | News 
28.11.2020 A tribute to some of the doctors who died from 
COVID-19  
Lancet | Obituary 
28.11.2020 Maintaining the HIV response in a world shaped 
by COVID-19 
Lancet | Editorial 
28.11.2020 Afghanistan braced for second wave of COVID-
19 
Lancet | World Report 
26.11.2020 Peter Doshi: Pfizer and Moderna’s “95% 
effective” vaccines – let’s be cautious and first 
see the full data 
BMJ |Opinion 
26.11.2020 The place for remdesivir in COVID-19 treatment Lancet Infectious Diseases  
25.11.2020 The domestic allocation of COVID-19 vaccines in 
low- and middle-income countries, who goes 
first? 
CGD | Blog 
25.11.2020 Why COVID-19 strengthens the case for a 
dedicated financing mechanism to scale up 
innovation in women’s, children’s, and 
adolescents’ health 
The Lancet Global Health | 
Comment 
25.11.2020 Certificate of COVID Vaccination: can we do 
better than the yellow card?  
CGD | Blog 
24.11.2020 Preventing a “return to normal”: addressing 
violence against women during COVID-19 
CGD | Blog 
24.11.2020 Remdesivir: a pendulum in a pandemic BMJ | Editorial 
23.11.2020 Hydroxychloroquine for COVID-19: Balancing 
contrasting claims 
Eur J Intern Med | 
Commentary 
  
   
 
Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
  
   
 
C19 Resource Hubs 
Global  Regional 
& Country 
Academic 
journals & 
Publishers 
Institutes/Centres/Funder
s/Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of 
the WHO 
ICL MRC Centre for 
Global Infectious Disease 
Analysis 
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University 
Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins University RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparedne
ss 
Innovations 
  Social 
Developm
ent Direct 
C19 blog 
series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID Repository     
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health 
Policy and 
Planning  
Norwegian Institute of 
Public Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent Epidemics      
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 
WHO & CGD 
Health systems 
Governance & 
Financing 
1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
Webinar  HSG TWG on CHWs 
with The George 
community health 
workers on the 
COVID-19 frontline 
Institute for Global 
Health 
19.11.2020 Looking at the 
pandemic with a 
gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
Online courses Varies WHO 
courses related to 
COVID19. 
Available 
now 
Standard 
precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, 
Modelling and Policy 
Online learning 2 weeks | 
2 hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays 
at 1700 
CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
Online learning 3 hours WHO 
for detection, 
prevention, response 
and control 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online learning Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel 
Coronavirus 
Online learning 3 weeks | 
4 hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online learning 3 weeks | 
3 hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 
1 hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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